Results of Local Recurrence in Patient with Breast Ductal Carcinoma In situ and Comparison with Low-Risk Groups in ECOG 5194 Study

INTRODUCTION: In this study, local recurrence rates and prognostic factors was investigated in patients with ductal carcinoma in situ (DCIS) after breast conserving surgery (BCS) and adjuvant radiotherapy (RT) and compared with Eastern Cooperative Oncology Group (ECOG) Study E5194. METHODS: Totally 96 patients were evaluated retrospectively. Prognostic factors that might influence local control (age, tumor size, surgical margins, nuclear grade, comedo necrosis, hormone receptor status) were investigated. The eligibility criteria of ECOG 5194 were stratified into two groups as in the original study and were compared for local control. RESULTS: The median follow-up time was 62 ay (8-139) months. Local recurrence was observed in 5 patients who had 2 (%2.1) invasive carcinoma and 3 (%3.1) DCIS. Ten years local control rate was 89%. In the recurrence of local disease, the age of 50 years, estrogen (ER) receptor negativity, c-erb-B2 positivity was found to be significant (respectively p=0.020, p=0.014, p=0.022). According to the ECOG study, Group 1 and Group 2, which are considered to be low risk groups, and these two groups were compared with those who were not included in these two groups; there was no difference in both comparisons (p> 0.05). DISCUSSION AND CONCLUSION: Prognostic factors affecting local control in DCIS have been age and hormone receptor status. When 10-year results were compared with the ECOG 5194, adjuvant RT produced an absolute difference of 10% in low-intermediate and high grade in local control.